Marketing of a Health Care Product
GlaxoSmithKline launched Requip for restless-legs syndrome and a few consumers heard of a problem, but some physicians were skeptical that a problem even existed. Despite these problems, the drug is now very successful. Should the marketing of a health care product that is not immediately recognized as responding to a health care need:
Have more government oversight and control?
Be left to allow market forces to decide it value?